Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2026-05-16 Proxy Solicitation & In…
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
Immediate Report
Proxy Solicitation & Information Statement Classification · 10% confidence The document is an SEC Schedule 14A – a proxy statement supplement filed as “Definitive Additional Materials” in connection with the company’s 2026 Annual Meeting of Stockholders. It provides clarifying information to the proxy materials and solicits votes for Proposal No. 2 (the 2026 Equity Incentive Plan). This is clearly Proxy Solicitation & Information Statement material (Schedule 14A), so it falls under Proxy Solicitation & Information Statement (PSI).
2026-05-16 English
Immediate Report
Report Publication Announcement Classification · 90% confidence The document is a short Immediate Report under Israeli regulations indicating that a Schedule 14A Proxy Statement Supplement (DEFA14A2_isa.pdf) is attached. It contains no substantive proxy or financial content itself, merely announcing publication of the report. Under the “menu vs. meal” rule, this is a Report Publication Announcement (RPA), not the actual proxy statement or information statement.
2026-05-16 English
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
Regulatory Filings Classification · 56% confidence The document is a press release announcing ModeX Therapeutics’ upcoming presentation of preclinical data at a scientific conference (ASGCT 2026 Annual Meeting). It does not contain financial results, management changes, regulatory filings, or detailed investor slide decks, nor is it an actual scientific report or investor presentation. It is a miscellaneous corporate announcement, which falls under the fallback “Regulatory Filings” category.
2026-05-12 English
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
Report Publication Announcement Classification · 92% confidence The document is an “Immediate Report” under Israeli Securities Regulations notifying the exchange that a press release (a report) is attached (“20260512PR_isa.pdf”). It is short (~2,000 characters) and merely announces the attached report rather than containing substantive data itself. Under the “menu vs meal” rule, this qualifies as a Report Publication Announcement rather than the report itself.
2026-05-12 English
Annual Report on Form 10-K
Regulatory Filings
2026-05-01 English
Annual Report on Form 10-K
Regulatory Filings
2026-05-01 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.